These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39111540)

  • 1. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms.
    Bouwman HB; Guchelaar HJ
    Drug Discov Today; 2024 Sep; 29(9):104134. PubMed ID: 39111540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in C5 and poor response to eculizumab.
    Nishimura J; Yamamoto M; Hayashi S; Ohyashiki K; Ando K; Brodsky AL; Noji H; Kitamura K; Eto T; Takahashi T; Masuko M; Matsumoto T; Wano Y; Shichishima T; Shibayama H; Hase M; Li L; Johnson K; Lazarowski A; Tamburini P; Inazawa J; Kinoshita T; Kanakura Y
    N Engl J Med; 2014 Feb; 370(7):632-9. PubMed ID: 24521109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The C5 gene polymorphism in patients with PNH].
    Nishimura J; Kanakura Y
    Rinsho Ketsueki; 2015 Feb; 56(2):103-10. PubMed ID: 25765788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
    Merrill SA; Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic variants in C5 and poor response to eculizumab].
    Nishimura J
    Rinsho Ketsueki; 2015 Jul; 56(7):855-60. PubMed ID: 26251149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [C5: eculizumab].
    Miyamoto K
    Brain Nerve; 2014 Oct; 66(10):1191-9. PubMed ID: 25296873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
    Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR
    J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab in pregnancy: a narrative overview.
    Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
    J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
    Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
    Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
    Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
    Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
    Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.